Leukemia, Myeloid, Acute: all 3,035 studies
Page 25 of 31. Open to participants first (746), then studies with results posted, then the rest; newest registration first within each.
- Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT01904643Phase 1
- A Safety Study of SGN-CD33A in AML PatientsCompletedNCT01902329Phase 1
- Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia PatientsStatus unknownNCT01889407
- Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic LeukemiaApproved for marketingNCT01869803
- Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33Status unknownNCT01864902Phase 1/2
- Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingNCT01861314Phase 1
- P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic MalignanciesCompletedNCT01854567Phase 3
- Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid LeukemiaCompletedNCT01843634Early Phase 1
- Sulindac for Patients With AMLWithdrawnNCT01843179Phase 2
- Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute LeukemiaCompletedNCT01842672Phase 1/2
- Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete RemissionCompletedNCT01842139Phase 1
- Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid LeukemiaCompletedNCT01839240Phase 1
- Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT01835288Phase 2
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT01834248Phase 1
- Brentuximab Vedotin + Re-induction Chemotherapy for AMLCompletedNCT01830777Phase 1
- Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AMLCompletedNCT01830361Phase 2
- Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 YearsStatus unknownNCT01828489Phase 3
- Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT)CompletedNCT01827579Phase 1/2
- Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01822015Early Phase 1
- Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01820624Phase 1
- Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related AplasiaCompletedNCT01819792Phase 4
- Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid HemopathyCompletedNCT01819558Phase 1/2
- Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCTCompletedNCT01810120Phase 1/2
- Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeStatus unknownNCT01809392Phase 2/3
- Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell TransplantationStatus unknownNCT01806116Phase 4
- Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid LeukemiaTerminatedNCT01801046Phase 1
- AR-42 and Decitabine in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01798901Phase 1
- Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic SyndromeTerminatedNCT01795924Phase 1/2
- Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell TransplantationCompletedNCT01795378Phase 1/2
- Mismatched Donor Cells to Treat Acute Myeloid LeukemiaStatus unknownNCT01793025Phase 1
- Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01787474Phase 1
- Conventional and Experimental Chemotherapy With Allogeneic Transplant in Young Patients With Acute Myeloid LeukaemiaStatus unknownNCT01785953
- Alisertib for Acute Myeloid LeukemiaCompletedNCT01779843Phase 1
- A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous LeukemiaCompletedNCT01773408Phase 1
- Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCTCompletedNCT01772953Phase 2
- Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS)TerminatedNCT01770158
- CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01768897Phase 1
- the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia PatientStatus unknownNCT01766375Phase 3
- Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood DisordersCompletedNCT01758042Not applicable
- Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT01757639Phase 1
- A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute LeukemiaCompletedNCT01756118Phase 1
- Family-mismatched/Haploidentical Donors Versus Matched Unrelated DonorsCompletedNCT01751997Phase 2/3
- Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD ProphylaxisTerminatedNCT01749111Phase 3
- Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell TransplantActive, not recruitingNCT01744223Phase 1/2
- DC Vaccination for Postremission Therapy in AMLCompletedNCT01734304Phase 1/2
- Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)CompletedNCT01723657Phase 2
- Risk-adapted Therapy for Adult Acute Myeloid Leukemia.CompletedNCT01716793Phase 2
- Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic SyndromeStatus unknownNCT01716364Phase 1
- Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT01701323Phase 1
- Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell TransplantationCompletedNCT01700751Phase 1
- Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid LeukemiaCompletedNCT01700413Phase 2
- Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）CompletedNCT01690507Phase 1/2
- Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AMLStatus unknownNCT01690065Phase 2
- Connect® Myeloid Disease RegistryTerminatedNCT01688011
- Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in RemissionActive, not recruitingNCT01686334Phase 2
- AML-MDS Novel Prognostic Tests Clinical StudyCompletedNCT01685619
- Lenalidomide Plus Chemotherapy for AMLCompletedNCT01681537Phase 1
- An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer StudiesCompletedNCT01677780Phase 1
- AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute LeukemiaTerminatedNCT01655875Phase 1
- Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic MalignanciesWithdrawnNCT01652014Phase 2
- Studying Biomarkers in Samples From Younger Patients With Acute Myeloid LeukemiaCompletedNCT01642121
- A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous LeukemiaCompletedNCT01641250Phase 1
- CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete RemissionWithdrawnNCT01639456Phase 2
- Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeTerminatedNCT01636609Phase 1
- A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous LeukemiaCompletedNCT01635296Phase 1
- Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell TransplantationCompletedNCT01634217Phase 1
- Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia PatientsStatus unknownNCT01633099Phase 3
- A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in RemissionCompletedNCT01632852Phase 1
- Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid LeukemiaCompletedNCT01629082Phase 1
- Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingNCT01627041Phase 2
- NK Cells in Cord Blood TransplantationStatus unknownNCT01619761Phase 1
- Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDSCompletedNCT01617226Phase 2
- Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML ConsolidationStatus unknownNCT01615757Phase 3
- A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) PatientsCompletedNCT01613976Phase 1
- Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic LeukemiaCompletedNCT01611116Phase 2
- Busulfan Pharmacokinetic Analysis and GST Pharmacogenetic Profile in Adults Undergoing Hematological Stem Cell TransplantationCompletedNCT01608204
- Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid MalignanciesCompletedNCT01606579Phase 1/2
- Registry on Hypomethylating Agents in Myeloid NeoplasmsCompletedNCT01595295
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
- 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid LeukemiaStatus unknownNCT01587430Phase 4
- Human Placental-Derived Stem Cell TransplantationCompletedNCT01586455Phase 1
- Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard InductionCompletedNCT01578954Phase 1
- Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01578109Phase 1
- Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid LeukemiaCompletedNCT01576185
- Safety Study of AKN-028 in Patients With Acute Myelogenous LeukemiaTerminatedNCT01573247Phase 1/2
- Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) PatientsTerminatedNCT01570465
- Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT01567059Phase 2
- Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantWithdrawnNCT01558778Not applicable
- The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).Status unknownNCT01556477Phase 2
- Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01555268Phase 1
- Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT01550185Phase 1
- Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid LeukemiaWithdrawnNCT01548911Phase 2
- TevaGastrim for Stem Cell Mobilization Sibling DonorsCompletedNCT01542944Phase 2
- VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic SyndromeCompletedNCT01541280Phase 2
- MRI Assessment of Leukemia Response to TherapyCompletedNCT01537159
- Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AMLStatus unknownNCT01534702Phase 1/2
- Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood UnitCompletedNCT01527838Phase 1
- Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid MalignanciesCompletedNCT01523223Phase 1
- Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction ChemotherapyTerminatedNCT01521936Phase 2
- Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic SyndromeWithdrawnNCT01520805Phase 2